[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anti-mag-neuropathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anti-mag-neuropathy":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,55],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100628458","studying-nerve-function-and-structure-in-charcot-marie-tooth-disease-anti-mag-neuropathy-and-cidp-100628458",false,"NCT07461896","Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP","Axonal Excitability and Ultrasound Patterns in Charcot-Marie-Tooth Disease and Other Demyelinating Disorders","CMT-NFS","Inclusion Criteria:\n\n1. The subject is ≥ 18 years old.\n\n   AND:\n2. A genetically confirmed diagnosis of one of the several CMT subtypes (i.e., CMT1A, CMT1B, CMTX1, CMT2I\u002FJ, CMT4B, CMT4D and CMT4J) OR\n3. A clinical diagnosis of either Chronic Inflammatory Demyelinating Polyneuropathy or anti-MAG polyneuropathy\n\nExclusion Criteria:\n\n1. Known neuropathy from another cause (e.g., diabetes, chronic renal insufficiency, medications, alcohol), including previous carpal tunnel syndrome surgery.\n2. History of exposure to chemotherapeutic agents (e.g., bortezomib, vincristine, cisplatin, taxol, vedotin\u002Fauromycin-conjugated antibodies), or other medications (e.g., disulfuram, thalidomide, voriconizole, chronic colchicine use) that can cause neuropathy, active alcohol abuse.\n3. History of cancer, other than skin cancer, within 5 years prior to enrollment.\n4. Pregnancy or nursing.\n5. Known systemic disease that predisposes to neuropathy.\n6. Other central nervous system diseases.","ALL","18 Years",{"count":20,"type":21},39,"ESTIMATED","OBSERVATIONAL","The project aims to perform both conventional nerve-conduction studies and axonal-excitability assessments using the TRONDF protocol in patients with selected forms of Charcot-Marie-Tooth disease, with comparison to individuals affected by dysimmune, acquired neuropathies, specifically chronic inflammatory demyelinating polyneuropathy (CIDP) and anti-MAG-neuropathy. The study further includes the analysis of nerve fibers obtained from skin biopsy in patients with CMT, as well as ultrasound evaluation of nerves (from the wrist to the axilla) and of intrinsic hand muscles. Axonal-excitability techniques involve the delivery of two electrical stimuli to the nerve under investigation; both stimuli vary in intensity, whereas only the first, known as the conditioning stimulus, varies in duration. Changes in response amplitude are then measured as these stimulation parameters are systematically adjusted. Some preliminary studies have already suggested the effectiveness of this method in distinguishing CMT1A from certain forms of acquired demyelinating disease, including acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and CIDP. Despite the promising results, only a limited number of studies have so far been conducted in humans and mice, and no comprehensive and systematic study has yet been carried out describing the changes in axonal excitability in the various CMT subtypes, either in humans or in mouse models.",[25,26,27,28,29],"Charcot-Marie-Tooth","CMT1A","Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","Polyneuropathy Associated With Anti-MAG Antibodies (Anti-MAG Polyneuropathy)","Anti-MAG Neuropathy",[25,31,32,33,26,34,35,36,37,38,39,40,41],"Neurophysiology","Axonal excitability","Ultrasound (US)","CMT1B","CMTX1","CMT2I\u002FJ","CMT4B2","CMT4D","CMT4J","CIDP","anti-MAG","RECRUITING","2026-03-06",{"date":45,"type":46},"2026-03-10","ACTUAL",{"date":48,"type":46},"2025-03-03",{"date":50,"type":21},"2026-05",{"name":52,"class":53},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":70,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100449783","phase-3-rituximab-therapy-in-anti-myelin-associated-glycoprotein-patients-with-characteristics-of-good-responders-100449783","NCT05136976","Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders","Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders:","THERAMAG","Inclusion Criteria:\n\n* Disease duration of 5 years or less and documented clinical worsening (clinical or ENMG or disability) over the past 24 months\n* IgM gammopathy, either MGUS or Waldenstrom Macroglobulinemia (WM)\n* Demyelinating polyneuropathy according to European Federation of Neurological Societies\u002FPeripheral Nerve Society guidelines for chronic inflammatory demyelinating polyneuropathy on nerve conduction studies.\n* Anti-MAG titre of 10 000 BTU or more\n* Total INCAT score of 1 point or more at baseline\n* Absence of immunoglobulin treatment within 3 months prior to inclusion.\n* Absence of immunosuppressive therapy within 6 months prior to inclusion, including steroid therapy of 2 months or more as part of the management of neuropathy.\n* Negative β-human chorionic gonadotropin (HCG) in women of childbearing potential\n* Women of childbearing potential must agree to use contraception for 365 days following administration of rituximab.\n\nExclusion Criteria:\n\n* \\- Unable to give informed consent\n* History of severe allergic or anaphylactic reaction to chimeric monoclonal antibody\n* Hypersensitivity known to one of the compounds of polaramine or methylprednisolone\n* Previous treatment with rituximab\n* Diseases known to cause polyneuropathy (e.g. diabetes, uncontrolled thyroid disease, vitamin B1 or B12 deficiency, renal (GFR \\\u003C 60ml ml\u002Fmin\u002F1,73 m2- Modification of Diet in Renal Disease (MDRD) formula) or liver disorder, myeloma, amyloidosis, cryoglobulinemia)\n* Indication of specific immunosuppressive therapy for WM\n* Significant uncontrolled disease at baseline such as cardiovascular (including cardiac arrhythmia), pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine or gastrointestinal or any other significant disease that may prevent patient from participating in the study\n* Congestive heart failure (NYHA III or IV)\n* Known active bacterial, viral, fungal mycobacterial infection\n* History or known presence of recurrent or chronic infection (e.g. viral hepatitis, HIV syphilis, tuberculosis).\n* History of cancer, including solid tumors and haematological malignancies (except basal cell and in situ squamous carcinoma of the skin, in situ carcinoma of the cervix of the uterus that have been excised and resolved, with documented clear margins on pathology)\n* History of alcohol (more than two drinks a day for a woman, more than 4 glasses a day for a man \\[World Health Organization (WHO) definition\\]) or other drug abuse within 6 months prior to randomization\n* History or currently active primary or secondary immunodeficiency\n* White blood cell count \\\u003C 1500\u002Fmm3 or platelet count \\\u003C 75 000\u002Fmm3\n* Angle closure glaucoma,\n* Urinary retention related to urethroprostatic disorders,\n* Uncontrolled psychotic disorders,\n* Severe liver failure,\n* Recent vaccination with live vaccines (\\\u003C3months) and vaccination with live virus vaccines is not recommended during the overall study period.",{"count":64,"type":21},90,"INTERVENTIONAL",[67],"PHASE3","Anti-MAG neuropathy is a progressively disabling orphan rare disorder due to a monoclonal immunoglobulin M(IgM) gammopathy displaying reactivity toward MAG, a glycoprotein of the peripheral nervous system. Its prevalence is around 1\u002F100000 and to date, no treatment has proven efficacy in this disease, including rituximab in 2 Randomized Controlled Trails(RCTs).",[29],[71,72,73,74,75],"Neuropathy","Anti-MAG","Rituximab","I-RODS","placebo","2025-11-21",{"date":78,"type":46},"2025-11-24",{"date":80,"type":46},"2023-06-29",{"date":82,"type":21},"2028-12",{"name":84,"class":53},"Centre Hospitalier Universitaire de Saint Etienne",15]